Gene, Cell and Tissue

Published by: Kowsar

Evaluation of Additional ABCC12 Gene Expression Character in Breast Cancer Samples Using Formal Diagnostic Profile

Maryam Esmaeili 1 , Sina Mirzaahmadi 1 , * and Golnaz Asaadi Tehrani 1
Authors Information
1 Department of Genetic, Islamic Azad University, Zanjan Branch, Zanjan, Iran
Article information
  • Gene, Cell and Tissue: 5 (4); e84392
  • Published Online: January 13, 2019
  • Article Type: Research Article
  • Received: September 18, 2018
  • Revised: December 27, 2018
  • Accepted: January 8, 2019
  • DOI: 10.5812/gct.84392

To Cite: Esmaeili M , Mirzaahmadi S , Asaadi Tehrani G . Evaluation of Additional ABCC12 Gene Expression Character in Breast Cancer Samples Using Formal Diagnostic Profile, Gene Cell Tissue. Online ahead of Print ; 5(4):e84392. doi: 10.5812/gct.84392.

Abstract
Copyright © 2019, Gene, Cell and Tissue. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Footnotes
References
  • 1. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420-5. doi: 10.1093/jnci/djh275. [PubMed: 15467030].
  • 2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 2010;127(12):2893-917. doi: 10.1002/ijc.25516. [PubMed: 21351269].
  • 3. Soheilyfar S, Velashjerdi Z, Sayed Hajizadeh Y, Fathi Maroufi N, Amini Z, Khorrami A, et al. In vivo and in vitro impact of miR-31 and miR-143 on the suppression of metastasis and invasion in breast cancer. J BUON. 2018;23(5):1290-6. [PubMed: 30570849].
  • 4. Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34-74. doi: 10.1016/j.phrs.2013.11.002. [PubMed: 24269963].
  • 5. Ahmadi M, Rasi H, Mostafazadeh M, Hajazimian S, Maroufi NF, Nahaei MR, et al. Analysis of cervical lesions for presence of HSV-2 and HPV-16 and HPV-18 in Iranian patients by PCR. Horm Mol Biol Clin Investig. 2017;31(3). doi: 10.1515/hmbci-2017-0019. [PubMed: 28609291].
  • 6. Sharif MA, Mamoon N, Mushtaq S, Khadim MT. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan. J Coll Physicians Surg Pak. 2009;19(2):99-103. [PubMed: 19208313].
  • 7. Hilton HN, Clarke CL, Graham JD. Estrogen and progesterone signalling in the normal breast and its implications for cancer development. Mol Cell Endocrinol. 2018;466:2-14. doi: 10.1016/j.mce.2017.08.011. [PubMed: 28851667].
  • 8. Lapidus RG, Nass SJ, Davidson NE. The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia. 1998;3(1):85-94. doi: 10.1023/A:1018778403001. [PubMed: 10819507].
  • 9. Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol. 2005;123(4):541-6. doi: 10.1309/YMJ3-A83T-B39M-RUT9. [PubMed: 15743737].
  • 10. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15(8):2894-904. doi: 10.1200/JCO.1997.15.8.2894. [PubMed: 9256133].
  • 11. Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol. 2006;24(19):3019-25. doi: 10.1200/JCO.2005.04.3034. [PubMed: 16754938].
  • 12. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92. doi: 10.1056/NEJM200103153441101. [PubMed: 11248153].
  • 13. Maher JM, Slitt AL, Cherrington NJ, Cheng X, Klaassen CD. Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (Mrp) family in mice. Drug Metab Dispos. 2005;33(7):947-55. doi: 10.1124/dmd.105.003780. [PubMed: 15802388].
  • 14. Augustine LM, Markelewicz RJ Jr, Boekelheide K, Cherrington NJ. Xenobiotic and endobiotic transporter mRNA expression in the blood-testis barrier. Drug Metab Dispos. 2005;33(1):182-9. doi: 10.1124/dmd.104.001024. [PubMed: 15494472].
  • 15. Bera TK, Iavarone C, Kumar V, Lee S, Lee B, Pastan I. MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc Natl Acad Sci U S A. 2002;99(10):6997-7002. doi: 10.1073/pnas.102187299. [PubMed: 12011458]. [PubMed Central: PMC124517].
  • 16. Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res. 2008;14(9):2601-8. doi: 10.1158/1078-0432.CCR-07-5026. [PubMed: 18451222].
  • 17. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-7. doi: 10.1200/JCO.2008.18.1370. [PubMed: 19204204]. [PubMed Central: PMC2667820].
  • 18. Perez EA, Cortes J, Gonzalez-Angulo AM, Bartlett JM. HER2 testing: Current status and future directions. Cancer Treat Rev. 2014;40(2):276-84. doi: 10.1016/j.ctrv.2013.09.001. [PubMed: 24080154].
  • 19. Dvorak P, Pesta M, Soucek P. ABC gene expression profiles have clinical importance and possibly form a new hallmark of cancer. Tumour Biol. 2017;39(5):1.0104283176998E+15. doi: 10.1177/1010428317699800. [PubMed: 28468577].
  • 20. El-Awady R, Saleh E, Hashim A, Soliman N, Dallah A, Elrasheed A, et al. The role of eukaryotic and prokaryotic ABC transporter family in failure of chemotherapy. Front Pharmacol. 2016;7:535. doi: 10.3389/fphar.2016.00535. [PubMed: 28119610]. [PubMed Central: PMC5223437].
  • 21. Hlavac V, Brynychova V, Vaclavikova R, Ehrlichova M, Vrana D, Pecha V, et al. The expression profile of ATP-binding cassette transporter genes in breast carcinoma. Pharmacogenomics. 2013;14(5):515-29. doi: 10.2217/pgs.13.26. [PubMed: 23556449].
  • 22. Kubelka-Sabit K, Filipovski V, Jasar D. Comparison of HER2 status in breast cancer patients using CISH and immunohistochemical protocols. Pathology. 2014;46. S55. doi: 10.1097/01.pat.0000454287.62515.99.
  • 23. Musa ZA, Qasim BJ, Al Shaikhly AWA. Evaluation of immunohistochemistry-equivocal (2+) HER2 gene status in invasive breast cancer by silver DNA in situ hybridization (SISH) and its association with clinicopathological variables. Iran J Pathol. 2017;12(1):9-19. [PubMed: 29760748]. [PubMed Central: PMC5938719].
  • 24. Madrid MA, Lo RW. Chromogenic in situ hybridization (CISH): A novel alternative in screening archival breast cancer tissue samples for HER-2/neu status. Breast Cancer Res. 2004;6(5):R593-600. doi: 10.1186/bcr915. [PubMed: 15318940]. [PubMed Central: PMC549176].
  • 25. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26(20):3324-30. doi: 10.1200/JCO.2007.14.2471. [PubMed: 18612148].
  • 26. Brase JC, Schmidt M, Fischbach T, Sultmann H, Bojar H, Koelbl H, et al. ERBB2 and TOP2A in breast cancer: A comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res. 2010;16(8):2391-401. doi: 10.1158/1078-0432.CCR-09-2471. [PubMed: 20371687].
  • 27. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358(13):1409-11. doi: 10.1056/NEJMc0801440. [PubMed: 18367751].
  • 28. Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012;131(3):1061-6. doi: 10.1007/s10549-011-1872-9. [PubMed: 22080245].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments